Overview

An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Status:
Completed
Trial end date:
2019-06-20
Target enrollment:
Participant gender:
Summary
28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
Spyryx Biosciences, Inc.
Treatments:
Pharmaceutical Solutions